How Pfizer’s grand gene therapy ambitions crumbled

Taking stock of the drug industry, from the lab to the medicine chest

July 26, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Spencer Platt/Getty Images STAT+ | How Pfizer's grand gene therapy ambitions crumbled The hemophilia treatment Pfizer reported on this week is a vestige of a much bigger effort to cure rare disease. By Jason Mast STAT+ | European regulators say Alzheimer's therapy Leqembi should be rejected The therapy, Eisai and Biogen's Leqembi, has received regulatory approval in the U.S. and a number of other countries. By Andrew Joseph Listen: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves Tara Bannow joins the podcast to talk about a new investigation into UnitedHealth's unrivaled physician empire. By Elaine Chen, Adam Feuerstein, and Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser